IRCT201306015605N1
Completed
Phase 2
The efficacy of complementory use of memantine in treatment of schizophrenia with chronic course
Clinical psychiatry research center, Tabriz university of medical sciences0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Schizophrenia.
- Sponsor
- Clinical psychiatry research center, Tabriz university of medical sciences
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Exclusion criteria:
- •Substance abuse; IQ of less than 70; Medical history of other mental disorder; Other clinical and neurological disorders; Taking antipsychotic medications during last week or long acting antipsychotic medications during past month; Receiving ECT in the past two weeks; Sensitivity to Memantine
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
The effectiveness of the combination of Memantine and Betahistine on insomnia severity, quality of life and severity of symptoms in people with primary tinnitusIRCT20190427043389N4Zanjan University of Medical Sciences60
Completed
Phase 2
Memantine effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N2Vice chancellor for research, Mazandaran University of Medical Sciences50
Recruiting
Phase 3
Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathychemotherapy-induced peripheral neuropathy in patients with cancer.Idiopathic peripheral autonomic neuropathyG90.0IRCT20160310026998N12Tabriz University of Medical Sciences180
Completed
Not Applicable
Evaluating the Effectiveness of Memantine on the Symptoms of Acute Mania in the Patients with Bipolar 1 DisorderBipolar I disorder.Bipolar affective disorder, current episode hypomanicIRCT2016121725031N6Vice Chancellor for Research of Arak University of Medical Sciences90
Recruiting
Not Applicable
Memantine for treatment of Obsessive-Compulsive DisorderIRCT20170123032145N4Iran University of Medical Sciences44